

Economic Evaluation in the MENA Region (2015-2025):  
A Targeted Review of Methodological Rigor and Policy Relevance

EE371

Y. Bassil, PharmD, L. Ghajar, PharmD, C. Saad, PharmD, L. Almualllem, MSc, MPH, M. Bechwati, PharmD, M. Matni, PharmD, R. Becker, MA  
CCHO FZ LLC, Dubai, United Arab Emirates



BACKGROUND

Health technology assessment (HTA) and cost-effectiveness evidence are increasingly critical to inform healthcare decision-making across the Middle East and North Africa (MENA)<sup>1</sup>. MENA remains underrepresented in global health economic literature<sup>2</sup>.

METHODOLOGY

A systematic PubMed search was conducted to identify economic evaluations (cost-effectiveness analysis [CEA] and/or cost-utility) published between January 2015 and June 2025 in MENA countries. Extracted data included country, year, disease area, population, intervention type, model type, perspective, and time horizon. Outcomes (e.g.; quality-adjusted life years [QALYs], incremental cost-effectiveness ratios [ICERs], disability-adjusted life years [DALYs]), utility sources, willingness-to-pay (WTP) thresholds, discount rates, and type of sensitivity analyses were collected to highlight regional trends. Of 270 screened records, 68 studies met eligibility criteria<sup>3-70</sup>.

RESULTS



Model Structure and Sensitivity Analysis

- Most evaluations used a healthcare system perspective, applied a 3% discount rate, and produced QALYs and ICERs as key outcomes<sup>3-70</sup>.
- Sensitivity analyses were commonly conducted, with probabilistic approaches increasingly reported after 2021<sup>3-70</sup>.
- Most studies relied on internationally derived utility values (e.g., United Kingdom [UK] EuroQol five-dimension questionnaire [EQ-5D]), and WTP thresholds were inconsistently applied, typically based on gross domestic product (GDP) multiples (1-3×).<sup>3-70</sup>

POLICY IMPLICATION

- Strengthening local data generation, standardizing methods, and aligning WTP thresholds with regional priorities can enhance relevance and policy impact.
- Building capacity and fostering regional collaboration can support sustainable HTA, improve transparency, and promote equitable resource allocation in MENA.

CONTACT INFORMATION


Younna Bassil, Senior HEOR Analyst  
CCHO FZ LLC, Dubai, United Arab Emirates  
Email address: youнна.b@ccho-ma.com

ACKNOWLEDGMENT


A special acknowledgment to key contributor: Dr. Christiane Maskineh, PhD.

OBJECTIVE

To assess the volume, methodological characteristics, disease focus, and policy relevance of full economic evaluations published between 2015-2025 in the MENA region and to identify key trends and evidence gaps.



Abbreviations: CEA, cost-effectiveness analysis; BIA, budget impact analysis; MENA, Middle East and North Africa.  
Figure 1. Flow diagram of study selection: total records screened, excluded, and included



\*\*One additional study included both Algeria and Tunisia, and two studies covered the entire MENA region.  
Figure 3. Regional Distribution of Publications Across MENA Countries




Figure 5. Model Types

CONCLUSION

Economic evaluations in the MENA region have increased in both volume and methodological rigor, particularly since 2022. However, geographic coverage and contextual relevance remain limited. To enhance the impact on regional decision-making, efforts should focus on:

- Adopting locally derived utility values and population norms.
- Establishing standardized, transparent WTP thresholds aligned with regional health priorities.
- Promoting capacity building in health economics and model-based evaluation methods.

SELECTED REFERENCES

1. Fasseeh A et al. HTA implementation in MENA: current vs preferred status. *Front Pharmacol*. 2020;11:15. doi:10.3389/fphar.2020.00015
2. Trowman R et al. Value and impact of HTA: 2023 HTAI Global Policy Forum. *Int J Technol Assess Health Care*. 2023;39(1):e75. doi:10.1017/S0269472723000263
3. Abushanab D et al. DTPD genotyping-guided adjuvant chemotherapy for breast cancer: cost-effectiveness analysis. *Clin Drug Invest*. 2025;45(3):151-163. doi:10.1007/s40261-024-01413-6
4. Almalik ZS et al. Cost-effectiveness of olaparib versus bevacizumab for RRMIS. *Clincoecon Outcomes Res*. 2025;17:217-232. doi:10.2147/COR.S303842
5. Inshasi J et al. Olaparib for relapsing MS in UAE: cost-effectiveness. *Ther Adv Neurol Disord*. 2025;18:17562864251330260. doi:10.1177/17562864251330260
6. Pollinger B et al. Pembrolizumab for TNBC in Egypt: cost-effectiveness. *J Med Econ*. 2025;28(11):105-113. doi:10.1080/13696998.2024.2441073
7. Soni MM et al. Kidney transplant vs hemodialysis in Dubai: cost-utility. *Value Health Prag Issues*. 2025;48:101109. doi:10.1016/j.vhri.2025.101109
8. Abushanab D et al. Add-on dapagliflozin for HFpEF without diabetes: cost-effectiveness. *J Med Econ*. 2024;27(1):404-417. doi:10.1080/13696998.2024.2322258
9. Abushanab D et al. Genotype-guided depression treatment in Qatar: cost-effectiveness. *J Pharm Policy Pract*. 2024;17(1):2410197. doi:10.1080/20525221.2024.2410197
10. Ali-Hessa R et al. Digital mental health vs usual care in Lebanon. *BMJ Ment Health*. 2024;11:e25544. doi:10.1136/bmjment-2023-000517
11. Adel AM et al. L-glutamine vs citrulline for sickle cell disease: cost-effectiveness from Qatar's perspective. *SAGE Open Med*. 2024;12:20503121231224551. doi:10.1177/20503121231224551
12. Alulhaidan M et al. Clinical and economic burden of therapeutic inertia in type 2 diabetes in Saudi Arabia. *Adv Ther*. 2024;41(11):1410-1452. doi:10.1007/s12325-024-02976-8
13. Al-Habib Alkhatib M et al. Cost-effectiveness of apixiciclovir for rheumatoid arthritis in Saudi Arabia. *J Med Econ*. 2024;27(1):134-144. doi:10.1080/13696998.2023.2299176
14. Al-Harsh E et al. High vs standard dose caffeine for neonatal apnea: cost-effectiveness analysis. *J Pharm Policy Pract*. 2024;17(1):2345218. doi:10.1080/20525221.2024.2345218
15. Alawadhi SM et al. Cost-effectiveness of IV resuscitation fluids in sepsis patients in Jordan. *J Med Econ*. 2024;27(1):126-133. doi:10.1080/13696998.2023.2296196
16. Elisi GH et al. Sodium zirconium cyclosilicate for hyperkalemia in CKD or heart failure: cost-effectiveness in Kuwait. *J Med Econ*. 2024;27(1):253-265. doi:10.1080/13696998.2024.2314930
17. Elazzazy S et al. CDK4/6 inhibitors for HR-HER2- advanced breast cancer: cost-effectiveness analysis. *Front Oncol*. 2024;14:1413676. doi:10.3389/fonc.2024.1413676
18. Elisi GH et al. Cost-effectiveness of anifrolumab vs belimumab in the UAE: microsimulation model. *J Med Econ*. 2024;27(suppl):23-34. doi:10.1080/13696998.2024.2320603
19. Hachicha-Makaj N et al. Universal antenatal HCV screening and treatment in Egypt: cost-effectiveness study. *BMJ Public Health*. 2024;2(1):e000517. doi:10.1136/bmjph-2023-000517



Scan QR code for full list of references.